Answers are grounded in this paper and cite their sources.
MAICs demonstrate improved clinical benefit of TALA+ENZA in metastatic castration-resistant prostate cancer, suggesting it as a viable treatment option.
MAICs showed improved clinical benefit with TALA+ENZA versus OLAP+AAP and NIRA+AAP across multiple mCRPC populations and endpoints. Despite limitations of indirect comparisons, findings support TALA+ENZA as a first-line treatment option for mCRPC.
No takes yet. Share an insight, caveat, or question.
Castro et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: